CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence

Trial Profile

CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Aug 2018

At a glance

  • Drugs Autologous muscle-derived stem cell therapy Cook MyoSite (Primary)
  • Indications Stress incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms CELLEBRATE
  • Sponsors Cook MyoSite
  • Most Recent Events

    • 31 Jul 2018 Planned End Date changed from 1 Aug 2023 to 1 Sep 2023.
    • 31 Jul 2018 Planned primary completion date changed from 1 Jul 2022 to 1 Sep 2022.
    • 31 Jul 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top